Verrica Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Verrica Pharmaceuticals reported 3rd quarter 2026 total revenue of $6.9 million, compared with $14.3 million in the 3rd quarter of 2025, which included a one-time $10 million milestone payment from Torrey.
- U.S. net Ycanth product revenue was a record $5.7 million, up 57.9% from the 3rd quarter of last year and approximately 11.9% from the 2nd quarter.
- Ycanth dispensed applicator units totaled 19,135, down 491 units from the previous quarter and up 35.8%, or 5,042 units, from the 3rd quarter of last year; management attributed the sequential decline to summer travel seasonality.
- Gross product margins were 89.8%, compared with 79.9% in the 3rd quarter of 2025. Research and development expenses were $7.6 million, selling, general, and administrative expenses were $10.4 million, and GAAP net loss was $12.4 million, or $0.58 per share.
- Non-GAAP net loss was $10.5 million, or $0.49 per share, compared with non-GAAP income of $1.1 million, or $0.12 per share, in the 3rd quarter of 2025.
- Cash was $14.4 million as of September 30th, 2026, including $12.5 million borrowed under the credit facility during the quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2026 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question-and-answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference.
Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals Third Quarter 2026 Corporate Update Conference Call. With me on the line this evening are Jayson Rieger, President and Chief Executive Officer, Noah Rosenberg, Chief Medical Officer, John Kirby, Interim Chief Financial Officer, and Chris Chapman, Chief Commercial Officer. As a reminder, during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verrica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verrica's SEC filings for important risk factors. Verrica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in expectations. In addition, during today's call, management will discuss certain non-GAAP financial measures.
These non-GAAP financial measures are in addition to and not a substitute for or superior to measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures compared to their closest GAAP equivalents. The earnings release that the company issued today includes GAAP to non-GAAP reconciliations for these measures and is also available on the Investor Relations section of Verrica's website. I'll now turn the call over to Verrica's President and CEO, Jayson Rieger.
Thank you, Kevin. Good evening, everyone, and thank you for joining us for our Third Quarter 2026 Corporate Update Call. We're so proud of our team's performance in the third quarter, as our commercial organization generated record YCANTH revenue for the second quarter in a row, while our research and development teams made major progress in our global phase III program to expand YCANTH's label to common warts, the largest unmet need in dermatology by prevalence. During the quarter, we announced the completion of enrollment in the first pivotal trial in the phase III program and greater than 50% enrollment in the second pivotal trial. Progress in each trial brings us closer to a possible expansion of YCANTH's label into what we believe could be a multi-billion dollar market for common warts.
Following the end of the quarter, we announced that we have unlocked the remaining $15 million of borrowing commitment from the credit facility we entered into in August, as we met the predefined operational and performance milestones established in the facility. The non-dilutive capital now available to draw, as needed, is expected to allow us to complete both pivotal studies in the Common Warts Program, with readouts from the studies expected in the first quarter and in mid-2027, respectively. Finally, I am excited to share that we are now exploring the development of VP-315 to treat patients with Gorlin syndrome, a rare genetic disease causing dozens or hundreds of basal cell carcinomas, or BCCs, over the patient's lifetime, often presenting them with substantial surgical fatigue and extensive scarring, and for which there are currently no approved therapies.
Our foundational data in sporadic BCC provides promise for the potential benefit of VP-315 for Gorlin patients, and we will provide more details about our plans as the clinical protocol, budget, and timelines are finalized. I will now discuss in more detail our commercial and clinical progress before turning the call over to Noah to provide some additional detail on the potential of treating Gorlin patients with VP-315, and finally to John to review our third quarter financial results. From a commercial perspective, in the third quarter of 2026, total revenue was $6.9 million, including a record U.S. YCANTH net product revenue of $5.7 million. This represents an increase of approximately 11.9% over the second quarter and a 57.9% increase over the third quarter of last year.
In the third quarter, dispensed applicator units for YCANTH totaled 19,135, down 491 units from the previous quarter and up 35.8%, or 5,042 units, from the third quarter of last year. We believe this decrease reflects summer travel seasonality impacting both patients and providers. The strong year-over-year revenue and unit growth reflects the continued successful execution of our commercial strategy based on expanding YCANTH distribution through both the specialty and retail pharmacy channels, which allows continued penetration into high-volume prescribers across dermatology, pediatric, and primary care offices. Consistent with the second quarter, we continue to generate strong growth demand from commercially insured patients, where our copay assistance programs play a critical role enabling patient access to YCANTH.
As always, our goal is to maximize patient access to what we believe is the most effective therapy in the treatment of molluscum, YCANTH, and we continue to work to anticipate and remove as many barriers to access as possible. With our prescriber retargeting and segmentation work that we discussed on our second quarter call now in place, we have turned our focus to driving both volume and yield, and have undertaken efforts to reduce prescription leakage and ensure optimal insurance coverage. The efforts that began with our YCANTH Rx non-dispensing pharmacy option, as well as other initiatives, have matured. During the third quarter, we began to realize the benefits of these efforts with an improvement in yield per prescription. With regards to YCANTH for molluscum, we continue to believe the largest competitive challenge is the historically entrenched watch-and-wait mindset that exists before any FDA-approved therapies were available.
We must work to ensure that patients with molluscum now realize that they have access to a highly effective treatment option that has the potential to induce higher and faster rates of clearance and reduce the spread of infection to others with earlier intervention. To that end, we generated and presented new analyses from our two registrational phase III trials of YCANTH for molluscum at two dermatology conferences in October. In these analyses, patients treated with YCANTH achieved complete clearance at a rate approximately four times faster than patients who were treated with placebo, and three times as many YCANTH-treated patients achieved complete clearance at each treatment visit. We believe these data analyses strongly support the practice of treating molluscum earlier in the course of infection, rather than simply taking a watch-and-wait approach that was common before YCANTH was approved.
Since announcing in July our exclusive distribution, marketing, and supply agreement with Medomie Pharma to commercialize YCANTH in Israel, we have been working with Medomie on their preparation activities to seek approval for YCANTH. We are pursuing many global expansion opportunities for YCANTH, as molluscum appears to affect children globally, irrespective of race, gender, or socioeconomic situation, and we see continued interest from potential partners around the world. Turning to our pipeline, we made major progress in our global phase III program studying YCANTH for the treatment of common warts during the third quarter. In August, we announced the completion of enrollment in COVE-2, the first pivotal phase III trial, after an interim analysis confirmed that no additional patients were recommended for enrollment. We expect top-line data from COVE-2 to be available in the first quarter of 2027.
Our clinical team has also enrolled patients in COVE-3, our second pivotal phase III trial, ahead of schedule. In late August, we announced that enrollment has exceeded 50% of its current target. We expect top-line data from this trial to be available by mid-2027. As a reminder, we are conducting the global phase III program with our development partner, Torii Pharmaceutical, which is funding the first $40 million of trial costs, representing approximately 90% of the current program budget. Research and development expenses for the program have been non-cash to date and will continue to be non-cash until Torii's funding commitment is exhausted toward the end of the program. Common warts affects approximately 22 million people in the U.S. alone, and there are no FDA-approved prescription therapies today. We believe label expansion of YCANTH into common warts could represent a multi-billion dollar commercial opportunity.
Given the substantial overlap of clinicians who see molluscum patients and also treat common warts, we believe that we could realize substantial commercial synergies from our existing commercial infrastructure upon launching into common warts, if approved. With respect to our VP-315 program for basal cell carcinoma, we continue to believe this asset has the potential to change the paradigm for treatment of BCC. In September and October, we present an encore poster at scientific conferences describing an exploratory analysis of potential abscopal-like effects of VP-315. I will now ask Noah to add further commentary on our VP-315 program and its potential to help patients with Gorlin syndrome.
Thank you, Jason. I am pleased to share a program update regarding VP-315, namely that we are exploring a proof-of-concept study of VP-315 in patients with Gorlin syndrome. As I will discuss more shortly, Gorlin patients live with a relentless burden of frequent basal cell carcinomas, and we believe VP-315 could change their treatment paradigm. Gorlin syndrome, also called basal cell nevus syndrome, is a rare genetic disorder usually caused by a mutation in the PTCH1 gene that overactivates the hedgehog signaling pathway. Patients can develop dozens to hundreds of BCC lesions over their lifetime, often starting in their teens or younger. Because new BCCs continue to appear and patients are highly sensitive to radiation, they often face a lifetime of repeated destructive surgical procedures, which leave cumulative scarring and disfigurement, along with a heavy psychological and quality of life burden.
Oral hedgehog inhibitors can help somewhat, but are not approved for this indication. Side effects to these drugs, such as muscle cramps, hair loss, and loss of taste, make their long-term use hard to tolerate. As I have said today, there is no therapy that is FDA approved specifically for the use in patients with Gorlin syndrome. Gorlin syndrome is a rare disease with a prevalence of an estimated 11,000 patients in the U.S. The Gorlin patient community has desperately sought an effective, safe, and tolerable non-surgical treatment option since the standard of care is so taxing. In this population, Gorlin experts have told us that even a modest reduction in the size and/or number of lesions could have a profound impact on patient quality of life and surgical burden.
In our previously disclosed phase II study of VP-315 for the treatment of sporadic BCC, injections of VP-315 produced a 97% objective response rate and an average 86% reduction in tumor size in treated lesions, with histological confirmation of complete clearance in over half of the subjects. In addition to these results in primary treated lesions, untreated lesions, which in some cases were distant to the primary injection site, also shrank by an average of 67%. Three of the 14 lesions in patients with additional untreated lesions cleared completely, further suggesting a potential abscopal response. The positive results observed in both primary and abscopal lesions are supportive for optimism that the sporadic BCC results may translate to patients with Gorlin syndrome.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
